MannKind | MNKD - Gross Profit On Sales


MannKind reported $7.77M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Adma Biologics USD 80.75M 8.07M Mar/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Insmed USD 356.19M 99.73M Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
MacroGenics USD 11.24M 19.87M Mar/2026
MannKind USD 7.77M 60.56M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 125.04M 76.09M Dec/2025
Novo Nordisk DKK 83.22B 19.21B Mar/2026
Pfizer USD -248M 11.29B Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026